Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Restructuring Costs (2016 - 2024)

Amicus Therapeutics (FOLD) has disclosed Restructuring Costs for 7 consecutive years, with $3.1 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Restructuring Costs changed N/A year-over-year to $3.1 million, compared with a TTM value of $3.1 million through Jun 2025, down 48.01%, and an annual FY2024 reading of $9.2 million, changed N/A over the prior year.
  • Restructuring Costs was $3.1 million for Q3 2024 at Amicus Therapeutics, down from $6.0 million in the prior quarter.
  • Across five years, Restructuring Costs topped out at $6.0 million in Q1 2024 and bottomed at $3.1 million in Q3 2024.